Evidence Grade C — Moderate human evidence. 55 published studies, 42 human. 4 registered clinical trials.
Medically reviewed by a licensed medical professional
Abarelix (previously sold as Plenaxis) was the first GnRH antagonist approved for prostate cancer — but it was withdrawn from the US market in 2005 after just two years due to serious allergic reactions. Despite its clinical failure, it was historically important as proof that GnRH antagonists could treat prostate cancer without the testosterone surge that limits older treatments.
Abarelix is also known by these brand and alternate names:
55 published studies: 42 human, 3 animal, 6 in-vitro, 19 reviews
Abarelix was marketed as Plenaxis (approved November 2003) with a highly restrictive indication — it was only approved for symptomatic advanced prostate cancer where no other treatment options existed, and required a mandatory prescriber registry and monitoring programme. It was withdrawn from the US market in May 2005.
The withdrawal was driven by reports of immediate-onset systemic allergic reactions, combined with the restricted indication limiting commercial uptake. Despite its clinical failure, abarelix was historically important as proof that GnRH antagonists could effectively treat prostate cancer without the testosterone flare. This directly enabled the development of degarelix (approved 2008) and relugolix (approved 2020), both of which addressed the safety concerns that ended abarelix's commercial life.
Abarelix works by directly blocking the GnRH receptor in the pituitary gland, immediately suppressing testosterone production without the initial hormone surge caused by GnRH agonists. While this mechanism was clinically effective, abarelix caused a higher rate of serious allergic reactions (including immediate-onset systemic reactions) compared to later GnRH antagonists. Research suggests this was related to the compound's tendency to trigger histamine release — a problem that was specifically designed out of the next-generation antagonist degarelix.
Research suggests abarelix effectively suppressed testosterone but caused immediate-onset systemic allergic reactions at rates that were unacceptable for a non-life-threatening indication. It was approved only under highly restrictive conditions — limited to symptomatic advanced disease where no alternatives existed, with a mandatory prescriber registry and monitoring programme. Abarelix's withdrawal directly enabled the development of safer successors: degarelix (approved 2008) addressed the allergic reaction problem, and relugolix (approved 2020) offered the first oral option. The compound serves as a cautionary example about immunogenicity in peptide drug development. No current research programmes exist.
PeptideTrace tracks 4 registered clinical trials for Abarelix sourced from ClinicalTrials.gov.
Diagnosis of Pelvic Endometriosis in MRI
The Plenaxis® Experience Study
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Abarelix is a synthetic decapeptide GnRH antagonist that was the first GnRH antagonist approved for prostate cancer. It was developed by Praecis Pharmaceuticals and marketed as Plenaxis. It has been withdrawn from the US market.
Abarelix competitively blocks the GnRH receptor, producing immediate testosterone suppression without the initial flare associated with GnRH agonists. Like degarelix, it directly blocks gonadotropin release. It was formulated as an intramuscular depot injection administered every two weeks initially, then monthly.
Abarelix was marketed as Plenaxis, approved November 25, 2003, with a highly restrictive indication (symptomatic advanced prostate cancer where no other treatment options exist) and a mandatory prescriber registry/monitoring program. It was withdrawn from the US market in May 2005 due to: (1) immediate-onset systemic allergic reactions including potential anaphylaxis (occurring in ~1.1% of patients); (2) poor commercial sales driven by the narrow indication and burdensome monitoring requirements; and (3) reports of declining testosterone suppression over time. The drug remains marketed in Germany and the Netherlands.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Kisspeptin-54 has no marketing authorisation. Phase II trials conducted primarily at Imperial College London have investigated its use as an IVF oocyte maturation trigger. One trial (60 patients) reported 95% oocyte maturation with zero cases of ovarian hyperstimulation syndrome. Kisspeptin-54 has a more advanced clinical evidence base than kisspeptin-10, with multiple Phase II studies in reproductive medicine. Its potential advantage over conventional IVF triggers relates to a lower risk of the serious complication of ovarian hyperstimulation. Clinical development is ongoing in academic settings. No Phase III trials have been completed.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
